Simvastatin is an inhibitor of hydroxy-methyl-glutaryl-coenzyme A reductase, used in the treatment of hypercholesterolemia. To enhance its bioavailability by inclusion complexation, as host molecule randommethyl--cyclodextrin had been used. After evaluating the complexes we chose the kneading product in 1:2 molar ratio for incorporation of 10 mg simvastatin tablets.
Introduction
Simvastatin (Figure 1 ) is a potent inhibitor of 3-hydroxy-3-methyl-glutaryl-coenzyme A (HMG-CoA) reductase. Th is enzyme catalyses the conversion of HMG-CoA to mevalonate, which is an early and rate-limiting step in the biosynthesis of cholesterol. However, it is practically insoluble in water and poorly absorbed from the gastrointestinal tract [1] .
By inclusion complexation of simvastatin with cyclodextrins its bioavailability can be enhanced [2] . Th erefore inclusion complexes are recommended to be used in formulations to obtain proper pharmaceutical forms.
Th e aim of this experimental work was the obtaining of uncoated tablets containing simvastatin inclusion complex as active ingredient and to observe the infl uence of excipients (disintegrants and lubricants) on the tablet properties. Th e inclusion complexes had been characterized in a previous article [3] . Th e main criteria of complex selection were solubility improvement and accessible obtaining method.
Th e used disintegrants: Primellose is chemically crosslinked sodium carboxymethyl cellulose. About three glucose units from four x are substituted with sodium carboxymethyl groups, and some of these groups are used to form cross links. Th e substituent groups disrupt hydrogen bonds that bind the cellulose chains tightly together and make sodium carboxymethyl cellulose very hydrophilic. Th e cross-links prevent dissolution of the polymer (which would lead to formation of a viscous gel). Th e optimized combination of substitution and cross-linking means that Primellose rapidly absorbs water and swells, the swelling resulting in the generation of a powerful disintegrating force within the tablets. Primellose is eff ective in combination fi ller-binders such as lactose at concentrations of 2-6% [4] ; Starch 1500 is a partially pregelatinized maize starch. Partial pregelatinization provides partial solubility, increased particle size, improved fl ow properties and compactibility.
Fillers fi ll out the size of the tablets, making it practical to produce and convenient for the consumer use. By Correspondence to: Emőke Rédai E-mail: remoke86@yahoo.com Fig. 1 . Simvastatin increasing the bulk volume, the fi llers make possible the fi nal product to have a proper volume for patient handling.
Tablettose® 100 is the brand-name for an agglomerated -lactose-monohydrate. Especially designed for directcompression, it combines the fl owability of coarse lactose and the good compressibility of fi ne milled lactose.
Corn starch has many functional properties including binding, disintegration, absorption, and bulking for pharmaceutical and nutraceutical applications including wet and dry granulation, tableting and body powders.
Materials and methods
Simvastatin (SIM) was kindly off ered by Labormed Pharma (Bucharest, Romania), randommethyl--cyclodextrin (RAMEB) by Cyclolab R&D Ltd (Budapest, Hungary). Potassium dhydrogen phosphate was supplied by Penta (Prague, Czech Republic), di-potassium hydrogen phosphate by Lachner (Prague, Czech Republic), Starch 1500 by Colorcon (Dartford, United Kingdom), Primellose by DFE Pharma (Goch, Germany), Tablettose 100 by Meggle GmbH (Wasserburg, Germany), Corn starch by Agrana (Aschach, Austria), magnesium stearate by Peter Greven (Vonlo, Th e Netherlands), talc by Luzenac Pharma (Spain). Solvents meet the requirements of the European Pharmacopoeia VIIth edition.
Th e inclusion complex was prepared by kneading in 1:2 molar ratio. For this purpose, we used ethanol 50c in equal amount with the sum of simvastatin (SIM) and randommethyl--cyclodextrin mass. Th e product (SRM12) was dried at 50°C by full evaporation of the solvent, and then it was pulverized to an average size of 200 μm (Retsch AS 200 sieve).
Th ere were prepared three formulations by direct compression, containing two diff erent superdisintegrants (Starch 1500 and Primellose), Tablettose 100 or corn starch as fi ller, magnesium stearate or talc as lubricant.
Weight variation test: Twenty tablets were taken determining their weights individually and collectively using a digital weighting balance. Th e average weight of one tablet was determined from the gross worked of mass collective weight. According to the European Pharmacopoeia not more than 2 of the individual masses deviate from the average mass by more than 7.5 % and none deviates by more than twice this percentage.
Hardness test, height and diameter: Hardness, height and diameter of the tablets were determined using Pharmatest 3 in1 Hardness, Diameter and Th ickness Tester.
Friability test: Ten tablets from each batch were examined for friability using Electrolab, Automated Friabilator EF-2, India. Th e equipment was run for 4 minutes at 25 revolutions per minute. Th e tablets were taken out, dedusted and reweighted and % friability was calculated. %Friability = (Loss in weight/Initial weight) × 100 In vitro disintegration time: Th e disintegration test was performed using an USP disintegration apparatus, with distilled water at 37 ± 0.5°C. Time required to obtain complete disintegration of six tablets were recorded and average was reported.
Th e dissolution profi le: It was obtained using an Erweka DT dissolution tester with paddle. For these studies there were taken 10 mg simvastatin and the tablets in 500 ml dissolution media, operating at 37 ± 1°C, stirring on a speed of 100 rpm. 5 ml aliquot was withdrawn at 5, 10, 15, 20, 25, 30 minutes, replaced with the same amount of dissolution media. Th e samples were estimated for amount of simvastatin dissolved by measuring the absorbance in UV at 239 nm. Dissolution studies were performed in triplicate.
Composition of the intestinal juice used as dissolution media: 11.94 g dipotassium hydrogen phosphate anhydride, 7.1 g potassium dihydrogen phosphate, adding distilled water to 1000 ml (pH = 7).
Dissolution profi le modeling: Th e drug-release kinetics was fi tted to fi rst-order, Probit, Logistic, Weibull, Gompertz and Korsmeyer-Peppas models. Th e best fi t model was chosen by R2 (determination coeffi cient) and MSE (Medium Square Error).
Results
Th e results concerning the weight uniformity, hardness, diameter and thickness test and friability are shown in Table  II . Th e disintegration times in minutes are given in Table  III . In vitro dissolution studies are shown in Figure 2 . Th e parameters of best fi t model are given in Table IV .
Discussion
In order to fi nd the most suitable formulation from the technological point of view several diff erent disintegrants were used, in the initial formulation phase. RAMEB is a powder with poor fl ow properties and sticking tendency. At direct compression RAMEB behaved as a powerful binder. Since its relatively big amount in the tablets (36%), superdisintegrants (Starch 1500 and Primellose) were needed in order to achieve a good disintegration [5] . Talc may be used in 1-10 % in the composition of tablets, associated or not with magnesium stearate. Th e platy nature of talc, the slipperiness that results from its crystalline Fig. 2 . In vitro dissolution studies structure, its softness and hydrophobicity all contribute to its performance as a glidant and lubricant in tableting. Th e eff ectiveness of talc glidant activity is dependent upon particle size compatibility between the talc and other powders in the formulation, improves direct compression tablet formulation disintegration behavior. Talc can eff ectively be used in combination with magnesium stearate for better disintegration and dissolution properties [6] .
All batches of the tablets were preliminarily evaluated for various physical parameters such as hardness, friability, disintegration. All above properties and values were close to boundary of standard limit. All the tablets maintained hardness in the range 78.3-113.1 N. Th e loss in total weight of the tablets due to the friability was in the range of 0.75-1.19 %. Formulation X, probably, due to the 6 % Primellose content, has lower hardness and friability over 1 %. Oral tablets normally have hardness higher than 40 N.
Th e result in vitro disintegration were within the prescribe limit and comply with the criteria for uncoated tablets, values were within 6-12 minutes [7] .
Dissolved amount of simvastatin from the tablets were between the dissolvent quantity of pure simvastatin (10%) and the inclusion complex (60%). Th e type of used disintegrant infl uences the dissolution profi le as well as the amount of it. Primellose confers better dissolution than Starch 1500. Phenomenom could be explained with the most adventagous chemical structure of the previous disintegrant. Unfortunately, the amount of talcum infl uences negatively the dissolution of simvastatin, formulation IV containing the greatest amount, possesses the lowest quantity of dissolved simvastatin. Fillers have less infl uence on dissolution.
Th e best fi t model proved to be the empiric Korsmeyer-Peppas (determination coeffi cients 0.968-0.985).
Conclusions
From our studies can be concluded that solubility of simavastatin can be improved by inclusion complex formation with randommethyl--cyclodextrin in 1:2 molecular ratio by kneading. Th e complex associated with disintegrant (Primellose), fi ller and glidants (talc and magnesium stearate) pressed into a conventional tablet provides better dissolution, than pure simvastatin. Th e physical parameters of 5% Primellose containing tablets comply with the requirements of European Pharmacopoeia. Th e dissolution of simvastatin is infl uenced by the disintegants and lubricants and can be described by the Korsemeyer Peppas model. Th e n parameter of this model permits the more profound elucidation of the liberation mechanism. Th e fact that n <0.5 indicates a Fickian transport. 
